Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

European Respiratory Journal

Volumn 46, Issue 6, 2015, Pages 1563-1576

  Getahun, Haileyesus ^a   Matteelli, Alberto ^a   Abubakar, Ibrahim ^b,c   Abdel Aziz, Mohamed ^a   Baddeley, Annabel ^a   Barreira, Draurio ^d   Den Boon, Saskia ^e   Gutierrez, Susana Marta Borroto ^f   Bruchfeld, Judith ^g   Burhan, Erlina ^h   Cavalcante, Solange ⁱ   Cedillos, Rolando ^j   Chaisson, Richard ^k   Chee, Cynthia Bin Eng ^l   Chesire, Lucy ^m   Corbett, Elizabeth ⁿ   Dara, Masoud ^a   Denholm, Justin ^o   De Vries, Gerard ^p   Falzon, Dennis ^a   Ford, Nathan ^a   Gale Rowe, Margaret ^q   Gilpin, Chris ^a   Girardi, Enrico ^r   Go, Un Yeong ^s   Govindasamy, Darshini ^t   Grant, Alison D ⁿ   Grzemska, Malgorzata ^a   Harris, Ross ^c   Horsburgh, C Robert ^u   Ismayilov, Asker ^v   Jaramillo, Ernesto ^a   Kik, Sandra ^w   Kranzer, Katharina ⁿ   Lienhardt, Christian ^a   LoBue, Philip ^x   Lönnroth, Knut ^a,y   Marks, Guy ^z   Menzies, Dick ^w   Migliori, Giovanni Battista ^aa   Mosca, Davide ^ab   Mukadi, Ya Diul ^ac   Mwinga, Alwyn ^ad   Nelson, Lisa ^a   Nishikiori, Nobuyuki ^a   Oordt Speets, Anouk ^ae   Rangaka, Molebogeng Xheedha ^b,af   Reis, Andreas ^a   Rotz, Lisa ^x   Sandgren, Andreas ^ag   Schepisi, Monica Sañé ^r   Schünemann, Holger J ^ah   Sharma, Surender Kumar ^a   Sotgiu, Giovanni ^ag   Stagg, Helen R ^aj   Sterling, Timothy R ^ak   Tayeb, Tamara ^al   Uplekar, Mukund ^ai   Van Der Werf, Marieke J ^ag   Vandevelde, Wim ^am   Van Kessel, Femke ^ae   Van'T Hoog, Anna ^an   Varma, Jay K ^x   Vezhnina, Natalia ^ao   Voniatis, Constantia ^ap   Noordegraaf Schouten, Marije Vonk ^ae   Weil, Diana ^a   Weyer, Karin ^a   Wilkinson, Robert John ^af,aq   Yoshiyama, Takashi ^ar   Zellweger, Jean Pierre ^as   Raviglione, Mario ^a   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d MINISTÉRIO DA SAÚDE   (Brazil)

^e Independant Consultant   (Switzerland)

^f INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF INDONESIA   (Indonesia)

ⁱ Funda??o Oswaldo Cruz   (Brazil)

^j Hospital Nacionale Rosales   (El Salvador)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l TAN TOCK SENG HOSPITAL   (Singapore)

^m TB Advocacy Consortium   (Kenya)

ⁿ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^o Victorian Tuberculosis Program Melbourne Health   (Australia)

^p KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^q PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^r NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^s Korea Centers for Disease Control and Prevention   (South Korea)

^t SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^u BOSTON UNIVERSITY   (United States)

^v Azerbaijan Ministry of Justice   (Azerbaijan)

^w MCGILL UNIVERSITY   (Canada)

^x CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^y KAROLINSKA INSTITUTE   (Sweden)

^z WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^aa WHO Collaborating Center for TB and Lung Diseases Fondazione S Maugeri   (Italy)

^ab INTERNATIONAL ORGANIZATION FOR MIGRATION   (Switzerland)

^ac UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^ad ZAMBART   (Zambia)

^ae Pallas Health Research and Consultancy BV   (Netherlands)

^af UNIVERSITY OF CAPE TOWN   (South Africa)

^ag EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^ah MCMASTER UNIVERSITY   (Canada)

^ai ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^aj UNIVERSITY OF SASSARI   (Italy)

^ak VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al MINISTRY OF HEALTH   (Saudi Arabia)

^am EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^an UNIVERSITY OF AMSTERDAM   (Netherlands)

^ao HIV TB and Penal System Projects   (Russian Federation)

^ap NICOSIA GENERAL HOSPITAL   (Cyprus)

^aq THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^ar Japan Anti Tuberculosis Association   (Japan)

^as Tuberculosis Competence Centre   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PLACEBO; RIFAMPICIN; RIFAPENTINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR;

AFRICA; ANTIBIOTIC RESISTANCE; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG USE; EUROPE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; IMMIGRANT; INCIDENCE; INCOME; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER TOXICITY; MEDICATION COMPLIANCE; META ANALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; ORGAN TRANSPLANTATION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISONER; REVIEW; SILICOSIS; SKIN MANIFESTATION; SOUTHEAST ASIA; SOUTHERN EUROPE; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; WESTERN HEMISPHERE; WORLD HEALTH ORGANIZATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COINFECTION; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; HEMODIALYSIS; HIV INFECTIONS; HOMELESS PERSON; KIDNEY FAILURE, CHRONIC; MASS SCREENING; MIGRANT; PUBLIC HEALTH; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS;

ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; COINFECTION; COMORBIDITY; DISEASE MANAGEMENT; DRUG USERS; EMIGRANTS AND IMMIGRANTS; EVIDENCE-BASED MEDICINE; HEALTH PERSONNEL; HIV INFECTIONS; HOMELESS PERSONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; KIDNEY FAILURE, CHRONIC; LATENT TUBERCULOSIS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PRISONERS; PUBLIC HEALTH; RADIOGRAPHY, THORACIC; RENAL DIALYSIS; RIFAMPIN; RISK ASSESSMENT; SILICOSIS; SUBSTANCE-RELATED DISORDERS; TRANSPLANT RECIPIENTS; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; WORLD HEALTH ORGANIZATION;

EID: 84949035058     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01245-2015     Document Type: Review

References (71)

1. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva, World Health Organization, 2015.
2. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
3. Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372: 2127-2135.
4. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138.
5. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603-622.
6. Uplekar M, Weil D, Lonnroth K, et al. WHO's new End TB Strategy. Lancet 2015; 385: 1799-1801.
7. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
8. World Health Organization. WHO Handbook for Guideline Development. 2nd Edn. Geneva, World Health Organization, 2014.
9. Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924.
10. Guyatt G, Oxman AD, Akl E, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-394.
11. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-382.
12. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725.
13. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength J Clin Epidemiol 2013; 66: 726-735.
14. Schunemann HJ, Oxman AD, Akl EA, et al. Moving from evidence to developing recommendations in guidelines: article 11 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc 2012; 9: 282-292.
15. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence J Clin Epidemiol 2013; 66: 140-150.
16. World Bank. Income Classification. http://data.worldbank.org/about/country-and-lending-groups Date last accessed: March 19, 2015.
17. World Health Organization. Global Tuberculosis Control: 2014 Report. Geneva, World Health Organization, 2014.
18. World Health Organization. Guidelines for Intensified Tuberculosis Case-finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-constrained Settings. Geneva, World Health Organization, 2011.
19. World Health Organization. Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-income Countries. Geneva, World Health Organization, 2012.
20. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project JAMA 1999; 282: 677-686.
21. van't Hoog AH, Langendam MW, Mitchell E, et al. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status. Report to WHO, 2013. www.who.int/tb/Review2Accuracyofscreeningtests.pdf?ua=1 Date last accessed: July 7, 2015. 2013.
22. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8: e1000391.
23. World Health Organization. Use of Tuberculosis Interferon-gamma Release Assays (IGRAs) in Low- and Middle-income Countries. Policy Statement. Geneva, World Health Organization, 2011.
24. Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014; 161: 419-428.
25. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
26. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41: 1125-1133.
27. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
28. Attamna A, Chemtob D, Attamna S, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax 2009; 64: 271.
29. Denholm JT, Leslie DE, Jenkin GA, et al. Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010. Int J Tuberc Lung Dis 2012; 16: 1320-1325.
30. Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
31. World Health Organization. A Practical Handbook on the Pharmacovigilance of Medicines Used in the Treatment of Tuberculosis: Enhancing the Safety of the TB Patient. Geneva, World Health Organization, 2012.
32. Sotgiu G, Matteelli A, Getahun H, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J 2015; 45: 1170-1173.
33. Public Health Agency of Canada. Canadian Tuberculosis Standards. 7th Edn. Canadian Thoracic Society and The Public Health Agency of Canada, 2014.
34. Centers for Disease Control and Prevention. Latent Tuberculosis Infection: a Guide for Primary Health Care Providers. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, 2013.
35. Ministry of Health (Sweden). Tuberkulos Vägledning för sjukvardspersonal. Stockholm, Ministry of Health, 2009. www.socialstyrelsen.se/smittskydd/sjukdomar/smittsammasjukdomarochsmittamnen/tuberkulos. Date last accessed: June 25, 2014. 2009.
36. NICE. Tuberculosis - Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. Manchester, National Institute for Health and Clinical Excellence, 2011.
37. Schaberg T, Bauer T, Castell S, et al. [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie 2012; 66: 133-171.
38. Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
39. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722.
40. Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis 2005; 9: 276-281.
41. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
42. Batki SL, Gruber VA, Bradley JM, et al. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend 2002; 66: 283-293.
43. Malotte CK, Hollingshead JR, Larro M. Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am J Prev Med 2001; 20: 103-107.
44. Tulsky J, Hahn J, Long H, et al. Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis 2004; 8: 83-91.
45. White MC, Tulsky JP, Goldenson J, et al. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med 2002; 162: 1044-1050.
46. Hirsch-Moverman Y, Colson P, Bethel J, et al. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis 2013; 17: 1178-1185.
47. Hovell MF, Sipan CL, Blumberg EJ, et al. Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. Am J Public Health 2003; 93: 1871-1877.
48. Kominski GF, Varon SF, Morisky DE, et al. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health 2007; 40: 61-68.
49. Nyamathi A, Christiani A, Nahid P, et al. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 2006; 10: 775-782.
50. Goldberg S, Wallace J, Jackson J, et al. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004; 8: 76-82.
51. Sawert H, Girardi E, Antonucci G, et al. Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Arch Intern Med 1998; 158: 2112-2121.
52. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010; 10: 7.
53. Burgos JL, Kahn JG, Strathdee SA, et al. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 2009; 13: 962-968.
54. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
55. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11: 919-925.
56. Schechter CB, Rose DN, Fahs MC, et al. Tuberculin screening: cost-effectiveness analysis of various testing schedules. Am J Prev Med 1990; 6: 167-175.
57. Brassard P, Steensma C, Cadieux L, et al. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a low-burden country. Pediatrics 2006; 117: e148-e156.
58. Chang S, Wheeler LS, Farrell KP. Public health impact of targeted tuberculosis screening in public schools. Am J Public Health 2002; 92: 1942-1945.
59. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
60. Linas BP, Wong AY, Freedberg KA, et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
61. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
62. Currie CS, Floyd K, Williams BG, et al. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005; 5: 130.
63. Linas BP, Wong AY, Freedberg KA, et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
64. Dasgupta K, Schwartzman K, Marchand R, et al. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162: 2079-2086.
65. Deuffic-Burban S, Atsou K, Viget N, et al. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 2010; 14: 471-481.
66. Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Public Health 2008; 8: 201.
67. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001270.
68. World Health Organization. Guidance on Ethics of Tuberculosis Prevention, Care and Control. Geneva, World Health Organization, 2010.
69. Denholm JT, Matteelli A, Reis A. Latent tuberculous infection: ethical considerations in formulating public health policy. Int J Tuberc Lung Dis 2015; 19: 137-140.
70. Kass NE. An ethics framework for public health. Am J Public Health 2001; 91: 1776-1782.
71. World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. Geneva, World Health Organization, 2013.